↓ Skip to main content

Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure

Overview of attention for article published in JACC: Heart Failure, April 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

policy
1 policy source
twitter
60 X users
facebook
3 Facebook pages

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure
Published in
JACC: Heart Failure, April 2017
DOI 10.1016/j.jchf.2017.01.008
Pubmed ID
Authors

Ståle H. Nymo, Pål Aukrust, John Kjekshus, John J.V. McMurray, John G.F. Cleland, John Wikstrand, Pieter Muntendam, Ursula Wienhues-Thelen, Roberto Latini, Erik Tandberg Askevold, Jørgen Gravning, Christen P. Dahl, Kaspar Broch, Arne Yndestad, Lars Gullestad, Thor Ueland, CORONA Study Group

Abstract

This study sought to evaluate whether a panel of biomarkers improved prognostication in patients with heart failure (HF) and reduced ejection fraction of ischemic origin using a systematized approach according to suggested requirements for validation of new biomarkers. Modeling combinations of multiple circulating markers could potentially identify patients with HF at particularly high risk and aid in the selection of individualized therapy. From a panel of 20 inflammatory and extracellular matrix biomarkers, 2 different biomarker panels were created and added to the Seattle HF score and the prognostic model from the CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) study (n = 1,497), which included conventional clinical characteristics and C-reactive protein and N-terminal pro-B-type natriuretic peptide. Interactions with statin treatment were also assessed. The two models-model 1 (endostatin, interleukin 8, soluble ST2, troponin T, galectin 3, and chemokine [C-C motif] ligand 21) and model 2 (troponin T, soluble ST2, galectin 3, pentraxin 3, and soluble tumor necrosis factor receptor 2)-significantly improved the CORONA and Seattle HF models but added only modestly to their Harrell's C statistic and net reclassification index. In addition, rosuvastatin had no effect on the levels of a wide range of inflammatory and extracellular matrix markers, but there was a tendency for patients with a lower level of biomarkers in the 2 panels to have a positive effect from statin treatment. In the specific HF patient population studied, a multimarker approach using the particular panel of biomarkers measured was of limited clinical value for identifying future risk of adverse outcomes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 60 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Netherlands 1 2%
Unknown 55 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 16%
Researcher 8 14%
Student > Bachelor 6 11%
Other 6 11%
Student > Doctoral Student 5 9%
Other 10 18%
Unknown 13 23%
Readers by discipline Count As %
Medicine and Dentistry 27 47%
Biochemistry, Genetics and Molecular Biology 6 11%
Veterinary Science and Veterinary Medicine 2 4%
Immunology and Microbiology 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 1 2%
Unknown 18 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2018.
All research outputs
#1,078,658
of 25,382,440 outputs
Outputs from JACC: Heart Failure
#335
of 1,583 outputs
Outputs of similar age
#21,738
of 323,961 outputs
Outputs of similar age from JACC: Heart Failure
#11
of 40 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.2. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,961 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.